![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Changes in Truvada® for HIV Pre-exposure
Prophylaxis Utilization in the USA: 2012-2016 - Disparities
|
|
|
Reported by Jules Levin
19th IAS Conference on HIV Science, 23-26 July 2017, Paris, France
Robertino Mera, David Magnuson, Trevor Hawkins, Staci Bush, Keith Rawlings, Scott McCallister
Gilead Sciences, Inc., Foster City, California, USA
![IAS1](../images/080117/080217-10/IAS1.gif)
![IAS2](../images/080117/080217-10/IAS2.gif)
![IAS3](../images/080117/080217-10/IAS3.gif)
![IAS4](../images/080117/080217-10/IAS4.gif)
![IAS5](../images/080117/080217-10/IAS5.gif)
![IAS6](../images/080117/080217-10/IAS6.gif)
References
1. Just Facts. www.justfacts.com/document/lifetime_risk_hiv.pdf;
2. Smith D, et al. MMWR Morb Mortal Wkly Rep 2015;64:1-6;
3. Mera-Giler R,
et al. 2015 National HIV Prevention Conference, abstr 1524;
4. Bush S, et al. ASM/ICAAC 2016, abstr 2651;
5. US Census Bureau. https://www.census.gov/quickfacts/table/PST045215/00;
6. Kaiser Family Foundation. http://kff.org/hivaids/fact-sheet/black-americans-and-hivaids-the-basics.
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|